You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
In vivo efficacy assessment of the CDK4/6 inhibitor palbociclib and the PLK1 inhibitor volasertib in human chordoma xenografts
|
|---|---|
| Published in |
Frontiers in oncology, November 2022
|
| DOI | 10.3389/fonc.2022.960720 |
| Pubmed ID | |
| Authors |
Thibault Passeri, Ahmed Dahmani, Julien Masliah-Planchon, Rania El Botty, Laura Courtois, Sophie Vacher, Elisabetta Marangoni, Fariba Nemati, Sergio Roman-Roman, Homa Adle-Biassette, Hamid Mammar, Sébastien Froelich, Ivan Bièche, Didier Decaudin |
X Demographics
The data shown below were collected from the profiles of 5 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| France | 3 | 60% |
| Switzerland | 1 | 20% |
| Netherlands | 1 | 20% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Scientists | 4 | 80% |
| Members of the public | 1 | 20% |
Mendeley readers
The data shown below were compiled from readership statistics for 6 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 6 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 2 | 33% |
| Student > Ph. D. Student | 1 | 17% |
| Student > Bachelor | 1 | 17% |
| Professor > Associate Professor | 1 | 17% |
| Unknown | 1 | 17% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 1 | 17% |
| Agricultural and Biological Sciences | 1 | 17% |
| Neuroscience | 1 | 17% |
| Medicine and Dentistry | 1 | 17% |
| Unknown | 2 | 33% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 December 2022.
All research outputs
#14,668,917
of 25,478,886 outputs
Outputs from Frontiers in oncology
#3,858
of 22,568 outputs
Outputs of similar age
#191,858
of 488,554 outputs
Outputs of similar age from Frontiers in oncology
#244
of 1,514 outputs
Altmetric has tracked 25,478,886 research outputs across all sources so far. This one is in the 41st percentile – i.e., 41% of other outputs scored the same or lower than it.
So far Altmetric has tracked 22,568 research outputs from this source. They receive a mean Attention Score of 3.0. This one has done well, scoring higher than 82% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 488,554 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 59% of its contemporaries.
We're also able to compare this research output to 1,514 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 82% of its contemporaries.